A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice

Pedro Henrique Q S Medeiros; David T Bolick; Solanka E Ledwaba; Glynis L Kolling; Deiziane V S Costa; Reinaldo B Oriá; Aldo Ângelo M Lima; Eileen M Barry; Richard L Guerrant

doi:10.1038/s41541-020-0180-y

A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice

NPJ Vaccines. 2020 Mar 27;5(1):30. doi: 10.1038/s41541-020-0180-y. eCollection 2020.

Authors

Affiliations

¹ 1Center for Global Health and Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA USA.
² 2Institute of Biomedicine, Federal University of Ceará, Fortaleza, CE Brazil.
³ 3Department of Microbiology, University of Venda, Thohoyandou, Limpopo province South Africa.
⁴ 4Center for Vaccine Development and Global Health, University of Maryland, Baltimore, MD USA.

Abstract

Vaccine studies for Shigella flexneri and enterotoxigenic Escherichia coli have been impaired by the lack of optimal animal models. We used two murine models to show that a S. flexneri 2a bivalent vaccine (CVD 1208S-122) expressing enterotoxigenic Escherichia coli colonization factor antigen-I (CFA/I) and the binding subunits A2 and B of heat labile-enterotoxin (LTb) is immunogenic and protects against weight loss and diarrhea. These findings document the immunogenicity and pre-clinical efficacy effects of CVD 1208S-122 vaccine and suggest that further work can help elucidate relevant immune responses and ultimately its clinical efficacy in humans.

Keywords: Bacterial infection; Experimental models of disease; Live attenuated vaccines; Preclinical research.

Abstract

Grants and funding